<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[reveal therapeutics]]></title><description><![CDATA[Innovating Drug Design with AI Precision]]></description><link>https://www.firstatomtx.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Tue, 07 Apr 2026 22:03:02 GMT</lastBuildDate><atom:link href="https://www.firstatomtx.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Asha Therapeutics Launches as First Atom Therapeutics, a Zero-Shot De Novo Drug Design Company]]></title><description><![CDATA[Asha Therapeutics is now First Atom Therapeutics]]></description><link>https://www.firstatomtx.com/post/asha-therapeutics-launches-as-first-atom-therapeutics-a-zero-shot-de-novo-drug-design-company</link><guid isPermaLink="false">69cc11232da60c15711fd2db</guid><pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/4f966d_d7a039dcdcb9477e9dae2fe52cb4b269~mv2.png/v1/fit/w_1000,h_776,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Business Wire</dc:creator></item><item><title><![CDATA[CMT Research Foundation Invests in Asha Therapeutics to Test Novel Drug for CMT2A]]></title><description><![CDATA[ATLANTA, GA, UNITED STATES, May 20, 2025 /EINPresswire.com/ -- CMT Research Foundation has invested in a research project with Asha...]]></description><link>https://www.firstatomtx.com/post/cmt-research-foundation-invests-in-asha-therapeutics-to-test-novel-drug-for-cmt2a</link><guid isPermaLink="false">699f0110a7ce06733ca37880</guid><pubDate>Tue, 20 May 2025 12:53:54 GMT</pubDate><dc:creator>EIN Presswire</dc:creator></item><item><title><![CDATA[Advancium Health Network Catalyzes Research on an Innovative SARM1 Inhibitor in a Rare Eye Disease]]></title><description><![CDATA[NEW YORK, April 23, 2025 /PRNewswire/ -- Advancium Health Network, a public charity dedicated to advancing therapies for rare diseases,...]]></description><link>https://www.firstatomtx.com/post/advancium-health-network-catalyzes-research-on-an-innovative-sarm1-inhibitor-in-a-rare-eye-disease</link><guid isPermaLink="false">699f0110a7ce06733ca3787d</guid><pubDate>Wed, 23 Apr 2025 04:00:00 GMT</pubDate><dc:creator>PR Newswire</dc:creator></item><item><title><![CDATA[Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association and Announces Appointment of Disarm Therapeutics’ Founders to SAB]]></title><description><![CDATA[November 13, 2024 09:30 AM Eastern Standard Time CINCINNATI--( BUSINESS WIRE )-- Asha Therapeutics  (Asha), a life sciences company...]]></description><link>https://www.firstatomtx.com/post/asha-therapeutics-awarded-barnett-drug-development-grant-by-the-als-association-and-announces-appoin</link><guid isPermaLink="false">699f0110a7ce06733ca37884</guid><pubDate>Wed, 13 Nov 2024 14:44:31 GMT</pubDate><dc:creator>Business Wire</dc:creator></item><item><title><![CDATA[Asha Therapeutics Announces the Nomination of a Novel Intra-Molecular Glue Development Candidate ASHA-624 as a Disease Modifying Therapeutic for Amyotrophic Lateral Sclerosis]]></title><description><![CDATA[CINCINNATI--(BUSINESS WIRE)--Asha Therapeutics (Asha) (www.ashatherapeutics.com), a life sciences company designing de novo disease...]]></description><link>https://www.firstatomtx.com/post/asha-therapeutics-announces-the-nomination-of-a-novel-intra-molecular-glue-development-candidate-ash</link><guid isPermaLink="false">699f0110a7ce06733ca37883</guid><pubDate>Mon, 01 Apr 2024 04:00:00 GMT</pubDate><dc:creator>Business Wire</dc:creator></item><item><title><![CDATA[Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year ]]></title><description><![CDATA[CINCINNATI--(BUSINESS WIRE)--Asha Therapeutics (Asha), (www.ashatherapeutics.com), a life sciences company, is leveraging its...]]></description><link>https://www.firstatomtx.com/post/asha-therapeutics-to-present-at-ad-pd-2024-international-conference-and-announces-clinical-developm</link><guid isPermaLink="false">699f0110a7ce06733ca37882</guid><pubDate>Sat, 09 Mar 2024 05:18:08 GMT</pubDate><dc:creator>Business Wire</dc:creator></item><item><title><![CDATA[Asha Therapeutics Selected as a BLUE KNIGHT™ Company by Johnson &#38; Johnson Innovation and BARDA]]></title><description><![CDATA[Asha Therapeutics (Asha), (www.ashatherapeutics.com), a biopharmaceutical company revolutionizing the traditional multi-year drug...]]></description><link>https://www.firstatomtx.com/post/asha-therapeutics-selected-as-a-blue-knight-company-by-johnson-johnson-innovation-and-barda</link><guid isPermaLink="false">699f0110a7ce06733ca3787c</guid><pubDate>Fri, 22 Sep 2023 19:06:23 GMT</pubDate><dc:creator>PR Newswire</dc:creator></item><item><title><![CDATA[Inside the Innovation Arena – A Recap of Our BLUE KNIGHT™ QuickPitch: Activating for the Future]]></title><description><![CDATA[August 31, 2023 - Earlier this week, innovation took center stage at the BLUE KNIGHT™ QuickPitch: Activating for the Future. 10...]]></description><link>https://www.firstatomtx.com/post/inside-the-innovation-arena-a-recap-of-our-blue-knight-quickpitch-activating-for-the-future</link><guid isPermaLink="false">699f0110a7ce06733ca37890</guid><pubDate>Fri, 01 Sep 2023 04:00:00 GMT</pubDate><dc:creator>JnJ Innovation</dc:creator></item><item><title><![CDATA[Asha TX to present breakthrough data for ASHA-044 targeting Beta-Catenin in colorectal cancer at NGIO]]></title><description><![CDATA[Asha Therapeutics will be presenting new data at the 6th Annual Next-Gen Immuno-oncology Conference showing robust efficacy of their Beta-Catenin targeted protein degrader (TPD) ASHA-044 in a CDX model of colorectal carcinoma (CRC). CRC is one of the most aggressive and metastatic tumors with incidence of disease skyrocketing over the past 5 years, particular in young ~40yr old populations. CRC tumors are typically characterized by the lack of appreciable immune cell infiltration, often...]]></description><link>https://www.firstatomtx.com/post/ngio2023</link><guid isPermaLink="false">699f0110a7ce06733ca3788b</guid><pubDate>Fri, 23 Jun 2023 16:32:18 GMT</pubDate><dc:creator>Asha TX</dc:creator></item><item><title><![CDATA[Targeting mitochondria in ME/CFS and Long Haul COVID with ASHA-091]]></title><description><![CDATA[Asha Therapeutics presented exciting new data for their lead Parkinson's Disease therapeutic ASHA-091 in one of its secondary indications...]]></description><link>https://www.firstatomtx.com/post/me-cfs</link><guid isPermaLink="false">699f0110a7ce06733ca3788a</guid><pubDate>Sat, 10 Jun 2023 20:27:45 GMT</pubDate><dc:creator>Asha TX</dc:creator></item><item><title><![CDATA[Asha Therapeutics Announces the Presentation of New Data on ASHA-1007, a Novel VHL Recruiter for TPD]]></title><description><![CDATA[See Full Press Release Here  Asha Therapeutics presented their novel VHL recruiter technology at Third Annual Ligase Targeting Drug...]]></description><link>https://www.firstatomtx.com/post/asha-therapeutics-announces-the-presentation-of-new-data-on-asha-1007-a-novel-vhl-recruiter-for-tpd</link><guid isPermaLink="false">699f0110a7ce06733ca37889</guid><pubDate>Thu, 13 Apr 2023 20:13:11 GMT</pubDate><dc:creator>Asha TX</dc:creator></item><item><title><![CDATA[Asha Therapeutics CSO, Dr. Bradlee Heckmann speaking at AD/PD 2023]]></title><description><![CDATA[Asha Therapeutics' scientific co-founder and CSO, Dr. Bradlee Heckmann will be presenting at the international AD/PD 2023 meeting in...]]></description><link>https://www.firstatomtx.com/post/asha-cso-dr-bradlee-heckmann-speaking-at-ad-pd-2023</link><guid isPermaLink="false">699f0110a7ce06733ca37888</guid><pubDate>Wed, 15 Mar 2023 18:04:00 GMT</pubDate><dc:creator>Asha TX</dc:creator></item><item><title><![CDATA[Asha Therapeutics Announces the Appointment of Dr. Craig Blackstone to its Board of Directors]]></title><description><![CDATA[February 10, 2023   Asha Therapeutics is pleased to announce the appointment of Dr. Craig Blackstone as a member of its Board of...]]></description><link>https://www.firstatomtx.com/post/asha-therapeutics-announces-the-appointment-of-dr-craig-blackstone-to-its-board-of-directors</link><guid isPermaLink="false">699f010fa7ce06733ca37876</guid><pubDate>Fri, 10 Feb 2023 16:46:52 GMT</pubDate><dc:creator>brad14380</dc:creator></item><item><title><![CDATA[Asha Therapeutics Appoints Kirsten Flowers to its Board of Directors]]></title><description><![CDATA[Asha Therapeutics (Asha), announced today the appointment of Kirsten Flowers to its Board of Directors. Asha’s PRISM™ technology has resulted in a pipeline of assets that treats neurological disease by considering neuronal deterioration and loss from multiple vantage points. Within Asha’s pipeline, lead asset ASHA-091 is a first-in-class, near clinic-ready custom-designed brain penetrant compound that restores the mitochondrial network, promoting cell survival over cell death in a number of...]]></description><link>https://www.firstatomtx.com/post/asha-therapeutics-appoints-kirsten-flowers-to-its-board-of-directors</link><guid isPermaLink="false">699f010fa7ce06733ca37875</guid><pubDate>Tue, 07 Feb 2023 22:06:41 GMT</pubDate><dc:creator>brad14380</dc:creator></item><item><title><![CDATA[Dr. Craig Blackstone, M.D., Ph.D., appointed as Chair, Asha Therapeutics’ Scientific Advisory Board]]></title><description><![CDATA[Asha Therapeutics www.ashatherapeutics.com announced today that it has appointed Dr. Craig Blackstone, Chief of the Movement Disorders...]]></description><link>https://www.firstatomtx.com/post/dr-craig-blackstone-m-d-ph-d-appointed-as-chair-asha-therapeutics-scientific-advisory-board</link><guid isPermaLink="false">699f010fa7ce06733ca37874</guid><pubDate>Fri, 07 Oct 2022 14:06:15 GMT</pubDate><dc:creator>brad14380</dc:creator></item><item><title><![CDATA[Asha Therapeutics presents at 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference]]></title><description><![CDATA[Sam Shrivastava (Asha CEO) and Dr. Bradlee Heckmann (Asha CSO) present updates on neuro-oncology assets and ASHA-044]]></description><link>https://www.firstatomtx.com/post/modern-day-meetings</link><guid isPermaLink="false">699f010fa7ce06733ca37872</guid><pubDate>Wed, 22 Jun 2022 03:22:16 GMT</pubDate><dc:creator>brad14380</dc:creator></item><item><title><![CDATA[ASHA-091 demonstrates efficacy in Parkinson’s Disease]]></title><description><![CDATA[Asha Therapeutics' lead mitochondrial dynamics targeting drug ASHA-091 demonstrates robust efficacy and safety in preclinical murine...]]></description><link>https://www.firstatomtx.com/post/balancing-checkbooks</link><guid isPermaLink="false">699f010fa7ce06733ca37873</guid><pubDate>Wed, 22 Jun 2022 03:22:16 GMT</pubDate><dc:creator>brad14380</dc:creator></item></channel></rss>